Skip to main content

Table 2 Results of the ductal cancer progression model from ref. 1 , applied to here presented patients

From: A model of immunohistochemical differences between invasive breast cancers and DCIS lesions tested on a consecutive case series of 1248 patients

Ductal breast cancer (DC) types Ductal breast cancer types Total
Luminal A Luminal B1 Luminal B2 HER2+ Triple-negative
DCIS A 34 6 12 10 6 68
IDC B 363 340 198 125 154 1180
Number of all DC (A + B) C 397 346 210 135 160 1248
% of cancer types in all DC   31.81% 27.72% 16.83% 10.82% 12.82% 100.00%
Probability of progression at the time of diagnosis (B/C) p 91.44% 98.27% 94.29% 92.59% 96.25% 94.55%
Number of progression t1/2 spent till the time of diagnosis log(1-p)/log(1/2)   3.55 5.85 4.13 3.75 4.74 4.20
Relative rate of progression from DCIS to IDC   84.46% 139.35% 98.36% 89.45% 112.84% 100.00%
Pooled reported DCIS and IDC data from ref. 1 Type Luminal A Luminal B HER2+ Triple-negative Total
  DCIS 153 53 96 26 328
  IDC 124 68 31 109 332
  Total 277 121 127 135 660
  Simulated population of all ductal breast cancer patients with 5% DCIS 2480.61 1329.43 677.90 2072.05 6560
  % of cancer types in simulated population 37.81% 20.27% 10.33% 31.59% 100.00%
  Probability of progression at the time of diagnosis 93.83% 96.01% 85.84% 98.75% 95.00%
  Number of progression t1/2 spent till the time of diagnosis 4.02 4.65 2.82 6.32 4.32
  1. The fastest in tissue invasion were Luminal B1 cancers and then the triple-negative cancers. Based on relative rates of tissue invasion it seems that criteria for Luminal B1 have really identified the most aggressive breast cancers.